NCT00154388View on ClinicalTrials.gov

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Life Threatening Diseases
Interventions
DRUG

Imatinib mesylate

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY